Discordance in tests used to detect inhibition of the P2Y12 receptor in patients undergoing interventional neuroradiology procedures
Background Clopidogrel is an inhibitor of the P2Y12 platelet receptor but testing to demonstrate a drug effect is controversial since there are often discordant results between different tests methods. Methods Samples from patients taking clopidogrel prior to intracranial flow-diversion procedures w...
Gespeichert in:
| Veröffentlicht in: | Interventional neuroradiology 2023-12, Vol.29 (6), p.655-664 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 664 |
|---|---|
| container_issue | 6 |
| container_start_page | 655 |
| container_title | Interventional neuroradiology |
| container_volume | 29 |
| creator | Gegri, Mansour Cheves, Tracey A Anderson, Matthew N McTaggart, Ryan Sweeney, Joseph D |
| description | Background
Clopidogrel is an inhibitor of the P2Y12 platelet receptor but testing to demonstrate a drug effect is controversial since there are often discordant results between different tests methods.
Methods
Samples from patients taking clopidogrel prior to intracranial flow-diversion procedures were tested using light transmission aggregometry (LTA), whole blood impedance aggregometry (WBIA) and the VerifyNow device (VND). Samples were classified as concordant if all test results were either responsive (inhibition) or resistant. Discordant results were separated using the VND into those with a responsive versus a resistant test result.
Results
Samples from 96 patients were studied. Concordance for all three tests was seen in 53/96 (55%) of samples, of which 41 (43%) were responsive and 12 (12%) were resistant. Discordance was observed in 43 samples (45%), 37 (28%) of which were caused by responsive VND and either a resistant WBIA or LTA and 6 (7%) of which were caused by a resistant VND but a responsive test result using either WBIA or LTA. These two discordant groups differed in both platelet count and hematocrit, but no such difference was present between the two concordant groups.
Conclusion
Discordance in P2Y12 inhibition testing may be partly explained by sample platelet count and hematocrit. |
| doi_str_mv | 10.1177/15910199221122858 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10680952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_15910199221122858</sage_id><sourcerecordid>2708257916</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-fb1612d4e0eecd4f48d6ab5e15f55b5a43ae4196a722fc050790c7fa89660fec3</originalsourceid><addsrcrecordid>eNp9UU1v1TAQtBCIPgo_gAvykUuK14md-IRQ-ZQq0UM5cLIce5PnKi8OtlOpd354Hb1SgZB6Wml2ZnY1Q8hrYGcAbfsOhAIGSnEOwHknuidkx-tOVJwBPCW7bV9thBPyIqVrxqSoFTwnJ7VktRJM7cjvjz7ZEJ2ZLVI_04wpJ7omdDQH6jCjzQXf-95nH2YaBpr3SC_5T-A0osUlh7gJF5M9zpt2dhjH4OexwBnjTUGL0kx0xjWGaJwPUxhv6RKDRbdGTC_Js8FMCV_dz1Py4_Onq_Ov1cX3L9_OP1xUtm66XA09SOCuQYZoXTM0nZOmFwhiEKIXpqkNNqCkaTkfLBOsVcy2g-mUlGxAW5-S90ffZe0P6Gz5LJpJL9EfTLzVwXj972b2ez2GGw1MdkwJXhze3jvE8GstWelDyQ-nycwY1qR5yzouWgWyUOFItTGkFHF4uANMb_Xp_-ormjd_P_ig-NNXIZwdCcmMqK_DGkuw6RHHO7lwptI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2708257916</pqid></control><display><type>article</type><title>Discordance in tests used to detect inhibition of the P2Y12 receptor in patients undergoing interventional neuroradiology procedures</title><source>Open Access: PubMed Central</source><source>MEDLINE</source><source>SAGE Journals</source><source>EZB Electronic Journals Library</source><creator>Gegri, Mansour ; Cheves, Tracey A ; Anderson, Matthew N ; McTaggart, Ryan ; Sweeney, Joseph D</creator><creatorcontrib>Gegri, Mansour ; Cheves, Tracey A ; Anderson, Matthew N ; McTaggart, Ryan ; Sweeney, Joseph D</creatorcontrib><description>Background
Clopidogrel is an inhibitor of the P2Y12 platelet receptor but testing to demonstrate a drug effect is controversial since there are often discordant results between different tests methods.
Methods
Samples from patients taking clopidogrel prior to intracranial flow-diversion procedures were tested using light transmission aggregometry (LTA), whole blood impedance aggregometry (WBIA) and the VerifyNow device (VND). Samples were classified as concordant if all test results were either responsive (inhibition) or resistant. Discordant results were separated using the VND into those with a responsive versus a resistant test result.
Results
Samples from 96 patients were studied. Concordance for all three tests was seen in 53/96 (55%) of samples, of which 41 (43%) were responsive and 12 (12%) were resistant. Discordance was observed in 43 samples (45%), 37 (28%) of which were caused by responsive VND and either a resistant WBIA or LTA and 6 (7%) of which were caused by a resistant VND but a responsive test result using either WBIA or LTA. These two discordant groups differed in both platelet count and hematocrit, but no such difference was present between the two concordant groups.
Conclusion
Discordance in P2Y12 inhibition testing may be partly explained by sample platelet count and hematocrit.</description><identifier>ISSN: 1591-0199</identifier><identifier>ISSN: 2385-2011</identifier><identifier>EISSN: 2385-2011</identifier><identifier>DOI: 10.1177/15910199221122858</identifier><identifier>PMID: 36039509</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Clopidogrel - therapeutic use ; Humans ; Original s ; Platelet Aggregation Inhibitors - pharmacology ; Platelet Aggregation Inhibitors - therapeutic use ; Platelet Function Tests - methods ; Purinergic P2Y Receptor Antagonists - pharmacology ; Purinergic P2Y Receptor Antagonists - therapeutic use ; Ticlopidine - pharmacology ; Ticlopidine - therapeutic use</subject><ispartof>Interventional neuroradiology, 2023-12, Vol.29 (6), p.655-664</ispartof><rights>The Author(s) 2022</rights><rights>The Author(s) 2022 2022 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c348t-fb1612d4e0eecd4f48d6ab5e15f55b5a43ae4196a722fc050790c7fa89660fec3</cites><orcidid>0000-0001-8990-6674</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680952/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680952/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,21799,27903,27904,43600,43601,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36039509$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gegri, Mansour</creatorcontrib><creatorcontrib>Cheves, Tracey A</creatorcontrib><creatorcontrib>Anderson, Matthew N</creatorcontrib><creatorcontrib>McTaggart, Ryan</creatorcontrib><creatorcontrib>Sweeney, Joseph D</creatorcontrib><title>Discordance in tests used to detect inhibition of the P2Y12 receptor in patients undergoing interventional neuroradiology procedures</title><title>Interventional neuroradiology</title><addtitle>Interventional Neuroradiology</addtitle><description>Background
Clopidogrel is an inhibitor of the P2Y12 platelet receptor but testing to demonstrate a drug effect is controversial since there are often discordant results between different tests methods.
Methods
Samples from patients taking clopidogrel prior to intracranial flow-diversion procedures were tested using light transmission aggregometry (LTA), whole blood impedance aggregometry (WBIA) and the VerifyNow device (VND). Samples were classified as concordant if all test results were either responsive (inhibition) or resistant. Discordant results were separated using the VND into those with a responsive versus a resistant test result.
Results
Samples from 96 patients were studied. Concordance for all three tests was seen in 53/96 (55%) of samples, of which 41 (43%) were responsive and 12 (12%) were resistant. Discordance was observed in 43 samples (45%), 37 (28%) of which were caused by responsive VND and either a resistant WBIA or LTA and 6 (7%) of which were caused by a resistant VND but a responsive test result using either WBIA or LTA. These two discordant groups differed in both platelet count and hematocrit, but no such difference was present between the two concordant groups.
Conclusion
Discordance in P2Y12 inhibition testing may be partly explained by sample platelet count and hematocrit.</description><subject>Clopidogrel - therapeutic use</subject><subject>Humans</subject><subject>Original s</subject><subject>Platelet Aggregation Inhibitors - pharmacology</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Platelet Function Tests - methods</subject><subject>Purinergic P2Y Receptor Antagonists - pharmacology</subject><subject>Purinergic P2Y Receptor Antagonists - therapeutic use</subject><subject>Ticlopidine - pharmacology</subject><subject>Ticlopidine - therapeutic use</subject><issn>1591-0199</issn><issn>2385-2011</issn><issn>2385-2011</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1v1TAQtBCIPgo_gAvykUuK14md-IRQ-ZQq0UM5cLIce5PnKi8OtlOpd354Hb1SgZB6Wml2ZnY1Q8hrYGcAbfsOhAIGSnEOwHknuidkx-tOVJwBPCW7bV9thBPyIqVrxqSoFTwnJ7VktRJM7cjvjz7ZEJ2ZLVI_04wpJ7omdDQH6jCjzQXf-95nH2YaBpr3SC_5T-A0osUlh7gJF5M9zpt2dhjH4OexwBnjTUGL0kx0xjWGaJwPUxhv6RKDRbdGTC_Js8FMCV_dz1Py4_Onq_Ov1cX3L9_OP1xUtm66XA09SOCuQYZoXTM0nZOmFwhiEKIXpqkNNqCkaTkfLBOsVcy2g-mUlGxAW5-S90ffZe0P6Gz5LJpJL9EfTLzVwXj972b2ez2GGw1MdkwJXhze3jvE8GstWelDyQ-nycwY1qR5yzouWgWyUOFItTGkFHF4uANMb_Xp_-ormjd_P_ig-NNXIZwdCcmMqK_DGkuw6RHHO7lwptI</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Gegri, Mansour</creator><creator>Cheves, Tracey A</creator><creator>Anderson, Matthew N</creator><creator>McTaggart, Ryan</creator><creator>Sweeney, Joseph D</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8990-6674</orcidid></search><sort><creationdate>20231201</creationdate><title>Discordance in tests used to detect inhibition of the P2Y12 receptor in patients undergoing interventional neuroradiology procedures</title><author>Gegri, Mansour ; Cheves, Tracey A ; Anderson, Matthew N ; McTaggart, Ryan ; Sweeney, Joseph D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-fb1612d4e0eecd4f48d6ab5e15f55b5a43ae4196a722fc050790c7fa89660fec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Clopidogrel - therapeutic use</topic><topic>Humans</topic><topic>Original s</topic><topic>Platelet Aggregation Inhibitors - pharmacology</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Platelet Function Tests - methods</topic><topic>Purinergic P2Y Receptor Antagonists - pharmacology</topic><topic>Purinergic P2Y Receptor Antagonists - therapeutic use</topic><topic>Ticlopidine - pharmacology</topic><topic>Ticlopidine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gegri, Mansour</creatorcontrib><creatorcontrib>Cheves, Tracey A</creatorcontrib><creatorcontrib>Anderson, Matthew N</creatorcontrib><creatorcontrib>McTaggart, Ryan</creatorcontrib><creatorcontrib>Sweeney, Joseph D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Interventional neuroradiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gegri, Mansour</au><au>Cheves, Tracey A</au><au>Anderson, Matthew N</au><au>McTaggart, Ryan</au><au>Sweeney, Joseph D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discordance in tests used to detect inhibition of the P2Y12 receptor in patients undergoing interventional neuroradiology procedures</atitle><jtitle>Interventional neuroradiology</jtitle><addtitle>Interventional Neuroradiology</addtitle><date>2023-12-01</date><risdate>2023</risdate><volume>29</volume><issue>6</issue><spage>655</spage><epage>664</epage><pages>655-664</pages><issn>1591-0199</issn><issn>2385-2011</issn><eissn>2385-2011</eissn><abstract>Background
Clopidogrel is an inhibitor of the P2Y12 platelet receptor but testing to demonstrate a drug effect is controversial since there are often discordant results between different tests methods.
Methods
Samples from patients taking clopidogrel prior to intracranial flow-diversion procedures were tested using light transmission aggregometry (LTA), whole blood impedance aggregometry (WBIA) and the VerifyNow device (VND). Samples were classified as concordant if all test results were either responsive (inhibition) or resistant. Discordant results were separated using the VND into those with a responsive versus a resistant test result.
Results
Samples from 96 patients were studied. Concordance for all three tests was seen in 53/96 (55%) of samples, of which 41 (43%) were responsive and 12 (12%) were resistant. Discordance was observed in 43 samples (45%), 37 (28%) of which were caused by responsive VND and either a resistant WBIA or LTA and 6 (7%) of which were caused by a resistant VND but a responsive test result using either WBIA or LTA. These two discordant groups differed in both platelet count and hematocrit, but no such difference was present between the two concordant groups.
Conclusion
Discordance in P2Y12 inhibition testing may be partly explained by sample platelet count and hematocrit.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>36039509</pmid><doi>10.1177/15910199221122858</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8990-6674</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1591-0199 |
| ispartof | Interventional neuroradiology, 2023-12, Vol.29 (6), p.655-664 |
| issn | 1591-0199 2385-2011 2385-2011 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10680952 |
| source | Open Access: PubMed Central; MEDLINE; SAGE Journals; EZB Electronic Journals Library |
| subjects | Clopidogrel - therapeutic use Humans Original s Platelet Aggregation Inhibitors - pharmacology Platelet Aggregation Inhibitors - therapeutic use Platelet Function Tests - methods Purinergic P2Y Receptor Antagonists - pharmacology Purinergic P2Y Receptor Antagonists - therapeutic use Ticlopidine - pharmacology Ticlopidine - therapeutic use |
| title | Discordance in tests used to detect inhibition of the P2Y12 receptor in patients undergoing interventional neuroradiology procedures |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T15%3A01%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discordance%20in%20tests%20used%20to%20detect%20inhibition%20of%20the%20P2Y12%20receptor%20in%20patients%20undergoing%20interventional%20neuroradiology%20procedures&rft.jtitle=Interventional%20neuroradiology&rft.au=Gegri,%20Mansour&rft.date=2023-12-01&rft.volume=29&rft.issue=6&rft.spage=655&rft.epage=664&rft.pages=655-664&rft.issn=1591-0199&rft.eissn=2385-2011&rft_id=info:doi/10.1177/15910199221122858&rft_dat=%3Cproquest_pubme%3E2708257916%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2708257916&rft_id=info:pmid/36039509&rft_sage_id=10.1177_15910199221122858&rfr_iscdi=true |